Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06101914 · ClinicalTrials.gov registry record
Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients
A clinical trial, sponsored by Power Life Sciences.
- Not yet
- Registry status
- 500
- Enrollment target
NCT06101914: Clinical Trial study, sponsored by Power Life Sciences.
NCT06101914 is a clinical trial that has not yet begun recruiting, run by Power Life Sciences. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06101914 has not yet begun recruiting, sponsored by Power Life Sciences.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-11 |
| Est. Completion | 2026-11 |
What is known before NCT06101914 opens enrollment
NCT06101914 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06101914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06101914 about?
NCT06101914 is a clinical study titled "Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients". Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence ...
What is the current status of trial NCT06101914?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2024-11. Estimated completion is 2026-11.
Who is sponsoring clinical trial NCT06101914?
This trial is sponsored by Power Life Sciences, which has 62 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia